EA200901610A1 - Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок - Google Patents

Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок

Info

Publication number
EA200901610A1
EA200901610A1 EA200901610A EA200901610A EA200901610A1 EA 200901610 A1 EA200901610 A1 EA 200901610A1 EA 200901610 A EA200901610 A EA 200901610A EA 200901610 A EA200901610 A EA 200901610A EA 200901610 A1 EA200901610 A1 EA 200901610A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenotype
function
acquired
hadjhok
biphenilkarboxamide
Prior art date
Application number
EA200901610A
Other languages
English (en)
Inventor
Кристине Диркс
Маркус Вармут
Сю Ву
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA200901610A1 publication Critical patent/EA200901610A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В изобретении предлагается способ модуляции активности сигнального пути Хеджхок. Прежде всего предлагается способ ингибирования аномальных состояний роста, опосредованных фенотипами, такими как фенотип с утраченной функцией Ptc, фенотип с приобретенной функцией Хеджхок, фенотип с приобретенной функцией smoothened или фенотип с приобретенной функцией Gli, и указанный способ заключается в том, что клетка контактирует с достаточным количеством соединения формулы I.
EA200901610A 2007-06-07 2008-06-04 Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок EA200901610A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94265407P 2007-06-07 2007-06-07
PCT/US2008/065816 WO2008154259A1 (en) 2007-06-07 2008-06-04 Biphenylcarboxamide derivatives as hedgehog pathway modulators

Publications (1)

Publication Number Publication Date
EA200901610A1 true EA200901610A1 (ru) 2010-06-30

Family

ID=39760140

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901610A EA200901610A1 (ru) 2007-06-07 2008-06-04 Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок

Country Status (13)

Country Link
US (1) US8507471B2 (ru)
EP (1) EP2162190B1 (ru)
JP (1) JP5373777B2 (ru)
KR (1) KR101217316B1 (ru)
CN (1) CN101820950B (ru)
AU (1) AU2008262056A1 (ru)
BR (2) BR122021010386B1 (ru)
CA (1) CA2688472C (ru)
EA (1) EA200901610A1 (ru)
ES (1) ES2569941T3 (ru)
HK (1) HK1147968A1 (ru)
MX (1) MX2009013273A (ru)
WO (1) WO2008154259A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93548C2 (ru) 2006-05-05 2011-02-25 Айерем Елелсі Соединения и композиции kak модуляторы хеджхоговского сигнального пути
BRPI0920533A2 (pt) * 2008-10-01 2020-12-15 Novartis Ag Antagonismo de estabilizado para o tratamento de distúrbios relacionados à trilha de porco-espinho
AR077490A1 (es) * 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
MX340670B (es) * 2009-08-25 2016-07-20 Abraxis Bioscience Llc * Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog.
RU2012125152A (ru) * 2009-11-18 2013-12-27 Новартис Аг Способы и композиции, предназначенные для лечения солидных опухолей и других злокачественных новообразований
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
TWI574687B (zh) * 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
SG194800A1 (en) * 2011-06-02 2013-12-30 Novartis Ag Biomarkers for hedgehog inhibitor therapy
KR101475115B1 (ko) * 2012-06-15 2014-12-23 중앙대학교 산학협력단 탐식작용 억제 효과를 가지는 자가 면역질환의 예방 또는 치료용 화합물
KR101485247B1 (ko) * 2012-06-26 2015-01-22 중앙대학교 산학협력단 신규 바이페닐―３―카르복스아마이드 유도체 또는 이의 염 및 이를 유효성분으로 함유하는 자가 면역질환 치료 또는 예방용 약학조성물
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
KR20150095792A (ko) * 2012-12-10 2015-08-21 메르크 파텐트 게엠베하 바이메소젠성 화합물 및 메소젠성 매질
US10343982B2 (en) * 2013-09-25 2019-07-09 Merck Patent Gmbh Compounds and mesogenic media
CN110099900B (zh) * 2016-12-27 2022-12-02 山东大学 针对Smoothened突变株的刺猬通路抑制剂
EP3624798A1 (en) 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
CN112773805B (zh) * 2019-11-11 2024-05-10 中国科学院脑科学与智能技术卓越创新中心 缺血性脑损伤的新型治疗药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
PL1745041T3 (pl) * 2004-04-30 2012-11-30 Genentech Inc Inhibitory chinoksalinowe szlaku sygnałowego hedgehog
PL1789390T3 (pl) * 2004-09-02 2012-04-30 Genentech Inc Pirydylowe inhibitory szlaku sygnałowego hedgehog
US20070038171A1 (en) 2005-07-25 2007-02-15 Mayer Peter L Shunt system
UA93548C2 (ru) * 2006-05-05 2011-02-25 Айерем Елелсі Соединения и композиции kak модуляторы хеджхоговского сигнального пути
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Also Published As

Publication number Publication date
CA2688472C (en) 2013-12-10
BR122021010386B1 (pt) 2021-08-03
US20100197659A1 (en) 2010-08-05
HK1147968A1 (en) 2011-08-26
KR101217316B1 (ko) 2012-12-31
CN101820950B (zh) 2015-01-21
EP2162190A1 (en) 2010-03-17
US8507471B2 (en) 2013-08-13
BRPI0812778A2 (pt) 2014-12-02
JP5373777B2 (ja) 2013-12-18
JP2010529963A (ja) 2010-09-02
EP2162190B1 (en) 2016-02-17
WO2008154259A1 (en) 2008-12-18
MX2009013273A (es) 2010-01-25
ES2569941T3 (es) 2016-05-13
AU2008262056A1 (en) 2008-12-18
KR20100028630A (ko) 2010-03-12
CA2688472A1 (en) 2008-12-18
CN101820950A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
EA200901610A1 (ru) Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок
EA200870504A1 (ru) Соединения и композиции в качестве модуляторов пути hedgehog
EA201100378A1 (ru) Модуляторы сигнального пути hedgehog
MX2007005125A (es) Compuestos y composiciones como moduladores de la senda de hedgehog.
WO2008014291A3 (en) Compounds and compositions as hedgehog signaling pathway modulators
WO2007120827A3 (en) Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
WO2012040499A3 (en) Metabolic inhibitors
GEP20146169B (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2007092190A3 (en) Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MY162604A (en) Heterocyclic compounds and uses thereof
MY165728A (en) Selective glycosidase inhibitors and uses thereof
WO2008061236A3 (en) Sulfoximines as kinase inhibitors
WO2010129816A3 (en) Heterocyclic compounds and uses thereof
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
SG170813A1 (en) New compounds
WO2010129467A8 (en) Compounds and methods for inhibition of renin, and indications therefor
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
IN2012DN02493A (ru)
MX2008010801A (es) Indolopiridinas como moduladores de quinesina eg5.
NO20090764L (no) 4-hydroksytiobenzamidderivater og legemidler
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander